Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Although coverage exceptions may be an option, the appeals process takes time ... Single-dose vials are available for $499 per month through the LillyDirect Zepbound Self Pay Journey Program, with the ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others. Should you?

Column: The Chicago Bulls keep drafting the same type of player. Will it ever pay off?

Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help ...

Citadel Securities has submitted a letter to the US Securities and Exchange Commission urging the agency to reject IEX Group’s proposal to launch a new options exchange. The letter warns that IEX’s ...

CVS Caremark is ending coverage of the popular weight-loss drug Zepbound effective July 1st, significantly impacting consumers. This shift is part of broader changes in the GLP-1 market, with ...